In this review on the CD70-CD27 axis, we focus on immunotherapeutic strategies aiming at eradicating the tumor cells by specifically targeting tumor-associated CD70 overexpression, thereby abrogating the immune suppressive effects driven by chronic stimulation of the CD70-CD27 axis. This evidence concerns the gene CD27 and neoplasm.